Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?

[Guest guest]

Gastroenterol Hepatol. 2011 May 5. [Epub ahead of print]

[Current treatment of hepatitis B infection: where do the new nucleos(t)ide

analogues fit in?]

[Article in Spanish]

Fuentes Olmo J, Uribarrena Amézaga R.

Source

Servicio de Aparato Digestivo, Hospital Universitario Servet, Zaragoza,

España.

Abstract

One of the most important advances made in the treatment of chronic hepatitis B

infection has been the development of nucleos(t)ide analogues. The first

antiviral agents used had limited efficacy due to the high resistance rate.

However, in the last few years, new agents (tenofovir, entecavir) have been

developed with greater antiviral potency and a lower resistance rate.

Consequently, these agents are considered to be the treatment of choice in the

most recent clinical guidelines. Nevertheless, interferon may still play an

important role in the treatment of hepatitis B in selected patients. Moreover,

in some contexts, such as renal insufficiency, pregnancy or immunosuppression,

the role of the new oral antiviral agents has not been precisely defined. The

present review analyzes these aspects, as well as some of the particular

features of the management of patients treated with nucleos(t)ide analogues.

Copyright © 2011 Elsevier España, S.L. All rights reserved.

PMID: 21550145 [PubMed - as supplied by publisher]

[Guest guest]

Gastroenterol Hepatol. 2011 May 5. [Epub ahead of print]

[Current treatment of hepatitis B infection: where do the new nucleos(t)ide

analogues fit in?]

[Article in Spanish]

Fuentes Olmo J, Uribarrena Amézaga R.

Source

Servicio de Aparato Digestivo, Hospital Universitario Servet, Zaragoza,

España.

Abstract

One of the most important advances made in the treatment of chronic hepatitis B

infection has been the development of nucleos(t)ide analogues. The first

antiviral agents used had limited efficacy due to the high resistance rate.

However, in the last few years, new agents (tenofovir, entecavir) have been

developed with greater antiviral potency and a lower resistance rate.

Consequently, these agents are considered to be the treatment of choice in the

most recent clinical guidelines. Nevertheless, interferon may still play an

important role in the treatment of hepatitis B in selected patients. Moreover,

in some contexts, such as renal insufficiency, pregnancy or immunosuppression,

the role of the new oral antiviral agents has not been precisely defined. The

present review analyzes these aspects, as well as some of the particular

features of the management of patients treated with nucleos(t)ide analogues.

Copyright © 2011 Elsevier España, S.L. All rights reserved.

PMID: 21550145 [PubMed - as supplied by publisher]